Nexalin Technology, Inc.

NXL

US65345B2016

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
1.35 ^USD	-5.59%		-6.90%	+233.50%

17/07	Nexalin Technology Says It Regains Nasdaq Compliance Following Stock Offering; Shares Fall	MT
01/07	Nexalin Technology Completes $5.3 Million Share Offering	MT

Nexalin Technology, Inc. has filed an IPO.

January 03, 2022 at 10:30 am IST

Nexalin Technology, Inc. has filed an IPO.

Security Name: Common Stock
Security Type: Common Stock
PriceRange: $5 to $7

Latest news about Nexalin Technology, Inc.

Nexalin Technology Says It Regains Nasdaq Compliance Following Stock Offering; Shares Fall	18/07	MT
Nexalin Technology Completes $5.3 Million Share Offering	02/07	MT
Top Midday Decliners	28/06	MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06	MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	28/06	MT
Top Premarket Decliners	28/06	MT
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal	26/06	CI
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency	19/06	CI
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	03/06	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	25/04	MT
Nexalin Technology Files $5.6 Million Shelf Registration	16/04	MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	09/04	CI
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	02/04	CI
Top Midday Gainers	28/03	MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28/03	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	14/03	CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	06/03	CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	08/02	CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	11/01	CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	16/23/16	CI
Nexalin Technology, Inc. Announces Resignation of Marilyn Elson as Chief Financial Officer	29/23/29	CI
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI

Chart Nexalin Technology, Inc.

Duration

Period

More charts

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEXALIN TECHNOLOGY, INC.	+233.50%	14.29M
THERMO FISHER SCIENTIFIC	+4.57%	212B
DANAHER CORPORATION	+8.61%	186B
INTUITIVE SURGICAL, INC.	+26.34%	151B
BOSTON SCIENTIFIC CORPORATION	+33.90%	114B
SIEMENS HEALTHINEERS AG	+2.81%	65.57B
EDWARDS LIFESCIENCES CORPORATION	+14.50%	52.61B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.8B
AGILENT TECHNOLOGIES, INC.	-3.98%	38.95B
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	37.64B